Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomic-Guided Chemotherapy in Advanced NSCLC
NCT00509366Phase 2Terminated
- Sponsor
- Duke University
- Start
- May 2007
- Primary completion
- Dec 2011
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Cisplatin micelle injection (HA132), gemcitabine, pemetrexed and docetaxel in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Duke University. Primary endpoint: Progression-Free Survival Rate at 1 year. Started May 2007; status: terminated.
02
Drugs
Cisplatin micelle injection (HA132)gemcitabinepemetrexeddocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00509366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509366.